Operating Profit Margin
since 2005
Calculation
Allergan PLC, operating profit margin, long-term trends, calculation
| Operating profit margin | = | 100 | × | Operating income (loss)1 | ÷ | Net revenues1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2019 | -27.63% | = | 100 | × | (4,445,300) | ÷ | 16,088,900) |
| Dec 31, 2018 | -39.57% | = | 100 | × | (6,247,600) | ÷ | 15,787,400) |
| Dec 31, 2017 | -37.15% | = | 100 | × | (5,921,200) | ÷ | 15,940,700) |
| Dec 31, 2016 | -12.53% | = | 100 | × | (1,825,500) | ÷ | 14,570,600) |
| Dec 31, 2015 | -20.00% | = | 100 | × | (3,014,500) | ÷ | 15,071,000) |
| Dec 31, 2014 | -9.71% | = | 100 | × | (1,267,700) | ÷ | 13,062,300) |
| Dec 31, 2013 | -4.88% | = | 100 | × | (423,200) | ÷ | 8,677,600) |
| Dec 31, 2012 | 5.42% | = | 100 | × | 320,800) | ÷ | 5,914,900) |
| Dec 31, 2011 | 11.70% | = | 100 | × | 536,200) | ÷ | 4,584,400) |
| Dec 31, 2010 | 8.56% | = | 100 | × | 305,400) | ÷ | 3,566,900) |
| Dec 31, 2009 | 13.75% | = | 100 | × | 383,900) | ÷ | 2,793,000) |
| Dec 31, 2008 | 14.12% | = | 100 | × | 358,128) | ÷ | 2,535,501) |
| Dec 31, 2007 | 10.24% | = | 100 | × | 255,660) | ÷ | 2,496,651) |
| Dec 31, 2006 | -21.33% | = | 100 | × | (422,096) | ÷ | 1,979,244) |
| Dec 31, 2005 | 13.27% | = | 100 | × | 218,512) | ÷ | 1,646,203) |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in thousands
Comparison to Competitors
Allergan PLC, operating profit margin, long-term trends, comparison to competitors
| Allergan PLC | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Moderna Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|
| Dec 31, 2019 | -27.63% | 39.03% | 43.57% | 18.25% | 19.38% | — | 28.10% | 17.99% |
| Dec 31, 2018 | -39.57% | 19.49% | 45.55% | 17.11% | 37.83% | — | 37.77% | 15.53% |
| Dec 31, 2017 | -37.15% | 33.99% | 45.76% | 16.48% | 55.04% | — | 35.41% | 14.19% |
| Dec 31, 2016 | -12.53% | 36.60% | 44.74% | 16.29% | 58.87% | — | 27.38% | 13.40% |
| Dec 31, 2015 | -20.00% | 32.97% | 40.44% | 16.87% | 69.03% | — | 30.51% | 13.77% |
| Dec 31, 2014 | -9.71% | 17.09% | 32.03% | 17.23% | 62.37% | — | 29.74% | 14.82% |
| Dec 31, 2013 | -4.88% | 30.14% | 32.25% | 17.13% | 41.87% | — | 36.11% | 12.30% |
| Dec 31, 2012 | 5.42% | 31.65% | 33.52% | 17.33% | 42.67% | — | 33.20% | 11.85% |
| Dec 31, 2011 | 11.70% | — | 28.19% | 16.27% | 46.77% | — | -46.02% | 10.62% |
| Dec 31, 2010 | 8.56% | — | 37.82% | 16.41% | 53.62% | — | -21.23% | 11.72% |
| Dec 31, 2009 | 13.75% | — | 38.37% | 13.79% | 54.55% | — | -19.54% | 10.38% |
| Dec 31, 2008 | 14.12% | — | 35.50% | 14.72% | 52.68% | — | -37.67% | 11.71% |
| Dec 31, 2007 | 10.24% | — | 27.81% | 15.79% | 57.98% | — | -91.55% | 10.00% |
| Dec 31, 2006 | -21.33% | — | 27.71% | 15.82% | -29.32% | — | -169.68% | 6.38% |
| Dec 31, 2005 | 13.27% | — | 40.33% | 15.84% | 61.41% | — | -187.97% | 10.01% |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).